Shots:
Barbara gave a comprehensive view of the P-III (MOMENTUM) clinical study results which evaluates its lead candidate in myelofibrosis
Sierra is now acquired by GSK (completed on 1st July 2022) resulting in GSK commercializing this prime product once approved
The interview outlines Sierra’s (now GSK) vision to develop transformative therapies for rare cancers
Smriti: Thank…
